AAP
DXCM icon

Aristotle Atlantic Partners’s DexCom DXCM Stock Holding History

Aristotle Atlantic Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
349,417
+97,932
+39% +$6.52M 0.98% 36
2026
Q1 		$15.8M Buy
251,485
+15,874
+7% +$1.11M 0.74% 43
2025
Q4 		$15.6M Buy
235,611
+42,334
+22% +$2.74M 0.72% 43
2025
Q3 		$13M Buy
+193,277
New +$15.3M 0.38% 51
2024
Q4 		– Sell
-199,445
Closed -$13.4M – 92
2024
Q3 		$13.4M Buy
199,445
+191
+0.1% +$15.7K 0.42% 53
2024
Q2 		$22.6M Sell
199,254
-1,208
-0.6% -$153K 0.73% 37
2024
Q1 		$27.8M Sell
200,462
-2,692
-1% -$338K 0.91% 33
2023
Q4 		$25.2M Buy
203,154
+2,323
+1% +$237K 0.89% 38
2023
Q3 		$18.7M Sell
200,831
-1,443
-0.7% -$163K 0.75% 45
2023
Q2 		$26M Buy
202,274
+36,544
+22% +$4.42M 0.98% 35
2023
Q1 		$19.3M Buy
165,730
+50
+0% +$5.6K 0.99% 38
2022
Q4 		$18.8M Sell
165,680
-17
-0% -$1.87K 1.05% 33
2022
Q3 		$13.3M Buy
165,697
+1,277
+0.8% +$108K 0.81% 44
2022
Q2 		$12.3M Buy
164,420
+2,916
+2% +$266K 0.94% 30
2022
Q1 		$20.7M Buy
161,504
+640
+0.4% +$70K 1.28% 27
2021
Q4 		$21.6M Buy
160,864
+776
+0.5% +$112K 1.25% 26
2021
Q3 		$21.9M Buy
160,088
+1,276
+0.8% +$161K 1.45% 28
2021
Q2 		$17M Buy
158,812
+156
+0.1% +$15K 1.12% 30
2021
Q1 		$14.3M Buy
158,656
+152
+0.1% +$14.3K 1.04% 33
2020
Q4 		$14.7M Buy
158,504
+3,696
+2% +$330K 1.13% 33
2020
Q3 		$16M Buy
154,808
+144
+0.1% +$15K 1.41% 27
2020
Q2 		$15.7M Buy
154,664
+40,496
+35% +$3.62M 1.51% 26
2020
Q1 		$7.69M Buy
+114,168
New +$7.1M 1.17% 30

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aristotle Atlantic Partners's DXCM Position: Q2 2026 in Review

Aristotle Atlantic Partners increased its DexCom (DXCM) stake by 39% in Q2 2026, buying an estimated $6.52M and bringing the position to 349,417 shares worth $23.5M. The position accounts for 0.98% of the portfolio, ranked #36.

Aristotle Atlantic Partners first reported a position in DXCM in Q1 2020 and has held it in 23 quarters since. The position peaked at $27.8M in Q1 2024. 972 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Aristotle Atlantic Partners held 349,417 shares of DexCom worth $23.5M as of Q2 2026.
  • Aristotle Atlantic Partners bought 97,932 DexCom shares in Q2 2026, an estimated $6.52M.
  • DexCom made up 0.98% of Aristotle Atlantic Partners's portfolio in Q2 2026, its #36 holding.
  • Aristotle Atlantic Partners first reported a position in DexCom in Q1 2020 and has held it in 23 quarters since.
  • Aristotle Atlantic Partners's DexCom position peaked at $27.8M in Q1 2024.
  • 972 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2026, filed 14 Aug 2026.